Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-251-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.77 million
Profitability
Miscellaneous
Employees145
Next Earnings Date2/26/2019 (Estimated)
OptionableOptionable
Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions
What is Heron Therapeutics' stock symbol?
Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."
How were Heron Therapeutics' earnings last quarter?
Heron Therapeutics Inc (NASDAQ:HRTX) issued its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.05. The biotechnology company had revenue of $19.79 million for the quarter, compared to analysts' expectations of $19.84 million. Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The firm's quarterly revenue was up 130.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.77) EPS. View Heron Therapeutics' Earnings History.
When is Heron Therapeutics' next earnings date?
What guidance has Heron Therapeutics issued on next quarter's earnings?
Heron Therapeutics updated its FY 2019 earnings guidance on Friday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $115-120 million, compared to the consensus revenue estimate of $174.08 million.
What price target have analysts set for HRTX?
11 brokerages have issued 1 year price targets for Heron Therapeutics' shares. Their forecasts range from $41.00 to $80.00. On average, they expect Heron Therapeutics' stock price to reach $53.70 in the next year. This suggests a possible upside of 97.9% from the stock's current price. View Analyst Price Targets for Heron Therapeutics.
What is the consensus analysts' recommendation for Heron Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heron Therapeutics.
What are Wall Street analysts saying about Heron Therapeutics stock?
Here are some recent quotes from research analysts about Heron Therapeutics stock:
- 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/9/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and expect upward earnings revisions, along with an approval of HTX-011, to drive HRTX shares higher. We expect upside to come from Cinvanti and HTX-011. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $50." (12/31/2018)
- 3. Mizuho analysts commented, "We expect HTX-011 to receive broad label and we see potential for a quicker review process by the FDA for a mid-2019 approval. We reiterate our Buy rating and raise our PT to $41." (6/22/2018)
- 4. Cowen Inc analysts commented, "We are still waiting to speak with the company and have thus not yet updated our model and price target, but do not recommend buying on weakness." (3/19/2018)
Has Heron Therapeutics been receiving favorable news coverage?
News stories about HRTX stock have been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Heron Therapeutics earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Heron Therapeutics' key competitors?
Some companies that are related to Heron Therapeutics include Beigene (BGNE), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG) and United Therapeutics (UTHR).
What other stocks do shareholders of Heron Therapeutics own?
Who are Heron Therapeutics' key executives?
Heron Therapeutics' management team includes the folowing people:
- Dr. Barry D. Quart, CEO & Director (Age 62)
- Mr. Robert H. Rosen, Pres & Director (Age 63)
- Mr. Robert E. Hoffman CPA, CFO & Sr. VP of Fin. (Age 53)
- Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)
- Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)
Who are Heron Therapeutics' major shareholders?
Heron Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.30%), Eagle Asset Management Inc. (2.16%), Orbimed Advisors LLC (1.79%), D. E. Shaw & Co. Inc. (1.35%), Northern Trust Corp (1.07%) and Geode Capital Management LLC (0.96%). Company insiders that own Heron Therapeutics stock include Barry D Quart, Kevin C Tang, Kimberly Manhard, Robert Hoffman and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.
Which institutional investors are selling Heron Therapeutics stock?
HRTX stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Orbimed Advisors LLC, First Trust Advisors LP, Eagle Asset Management Inc., Chartwell Investment Partners LLC, Asymmetry Capital Management L.P., Virginia Retirement Systems ET AL and MetLife Investment Advisors LLC. Company insiders that have sold Heron Therapeutics company stock in the last year include Barry D Quart, Kevin C Tang, Kimberly Manhard, Robert Hoffman and Robert Rosen. View Insider Buying and Selling for Heron Therapeutics.
Which institutional investors are buying Heron Therapeutics stock?
HRTX stock was bought by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., BlackRock Inc., Ontario Teachers Pension Plan Board, Candriam Luxembourg S.C.A., Fosun International Ltd, Sofinnova Investments Inc., New York State Common Retirement Fund and Bank of Montreal Can. View Insider Buying and Selling for Heron Therapeutics.
How do I buy shares of Heron Therapeutics?
Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heron Therapeutics' stock price today?
One share of HRTX stock can currently be purchased for approximately $27.14.
How big of a company is Heron Therapeutics?
Heron Therapeutics has a market capitalization of $2.12 billion and generates $30.77 million in revenue each year. The biotechnology company earns $-197,480,000.00 in net income (profit) each year or $3.65 on an earnings per share basis. Heron Therapeutics employs 145 workers across the globe.
What is Heron Therapeutics' official website?
How can I contact Heron Therapeutics?
Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]
MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
